Theraclone doses first patient in Phase 1 TCN-032 drug trial
TCN-032 was discovered utilizing Theraclone’s I-STAR platform. The trial aims to investigate the safety profile of a single intravenous administration of TCN-032 compared to placebo. The study expects
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.